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Volume 50, Number 3 Abstracts 701Cyclical Ischaemic Preconditioning Modulates the Adaptive Immune
Response in Human Limb Ischaemia-Reperfusion Injury
Sullivan PJ, Sweeney KJ, Hirpara KM, et al. Brit J Surg 2009;96:381-390.
Conclusion: Limb reperfusion injury can be modulated by ischemic
preconditioning.
Summary: Ischemic preconditioning of reperfused tissues occurs when
tissues are exposed for a short period to ischemia and then followed by a
recovery period free of the stimulus. This seems to render them more
resistant to subsequent ischemia-reperfusion injury.Mechanisms of ischemic
preconditioning are poorly understood. It is known that ischemia and
ischemic preconditioning can have effects on both innate and adaptive
immune systems. In this study, the authors hypothesize modulation of T-cell
function may be a mechanism by which ischemic preconditioning confers
protection against reperfusion injury.
The authors evaluated systemic T-cell populations for their function and
activation in patients undergoing anterior cruciate ligament repair using a
tourniquet. Patients were included if they had no other comorbidities, took no
regular medication, and were otherwise healthy. There were 25 patients ran-
domized to preconditioning or control. In patients undergoing ischemic pre-
conditioning during anterior cruciate repair, the leg operated on was elevated
and exsanguinated; then, the tourniquet was inflated to at least 100 mm Hg
greater than systolic blood pressure. Inflation wasmaintained for 5minutes and
then released for 5 minutes. Two further cycles of preconditioning were per-
formed in the treated patients. In control patients, a tourniquet was applied but
was not inflated before the actual inflation of the tourniquet for the operation.
Systemic levels of interleukin (IL) 4 and interferon- and surface expression of
CD45ro/ra and CD62L and CD95 were measured. T cells were examined
systemically and in simulated serum co-culture to determine CD4/CD8 and
Th1/Th2 shifts through intercellular cytokine production.
Without ischemic preconditioning, CD4 and CD45ro cell numbers
increased after reperfusion injury. CD8 cells expressing CD45ro and CD95
increased with ischemic preconditioning. Preconditioning serum in co-
culture attenuated increases in CD4 and decreases in CD8 cell numbers.
After reperfusion injury, IL-2 levels were lower after ischemic precondition-
ing. Co-culture with post-reperfusion injury serum increased proinflamma-
tory intercellular cytokine production.
Comment: The data indicate ischemic preconditioning prevents
lymphocyte-directed immune dysfunction through activation and proinflam-
matory cytokine production by CD4 cells, at the same time preventing
CD4/CD8 cellular derangement. The systemic cellular and cytokine
changes observed lend support to a possible role for circulating lymphocytes
in remote ischemic preconditioning. (Remote ischemic preconditioning is
where ischemia is administered to tissues that will not themselves undergo
reperfusion injury.) Patients likely to have a marked reperfusion injury may
be considered for remote ischemic preconditioning while their urgent
ischemic condition is being treated.
Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
Dixon BS, Beck GJ, VazquezMA, et al. N Engl JMed 2009;360:2191-201.
Conclusion: Use of the combination of dipyridamole plus aspirin
reduces risk of stenosis and improves duration of primary unassisted patency
of newly created arteriovenous grafts.
Summary: Arteriovenous grafts remain a common source for dialysis
access. Although it is generally possible to restore patency to arteriovenous grafts
after thrombosis, such procedures are costly. The annual cost of procedures
related to vascular access is estimated to exceed $1 billion in the United States
(US Renal Data System. 2007 Annual data report: atlas of end-stage renal
disease in the United States. Bethesda, MD: National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney Diseases, 2007). It is
postulated that because dipyridamole acts by inhibiting the proliferation of
vascular smoothmuscle cells and that its use in treatment of patients with newly
created hemodialysis accessmay improve patency of the dialysis access graft. The
authors therefore performed a randomized, double-blind, placebo-controlled
trial to determine whether extended-release dipyridamole plus aspirin inhibited
stenosis of vascular access and prolonged primary unassisted patency of newly
created dialysis access grafts.
Patients were randomized to receive dipyridamole at a dose of 200 mg
and aspirin at a dose of 25 mg twice daily, or placebo, after placement of a
new arteriovenous dialysis access graft. The primary outcome was loss of
primary unassisted patency of the access graft. Secondary outcomes included
cumulative graft failure and death.
Thirteen centers in the United States participated in the study, and 649
patients were randomly assigned to receive dipyridamole plus aspirin (321
patients) or placebo (328 patients). The study extended for 4.5 years, with
an additional 6 months of follow-up. Blood flow rates at access sites were
measured each month after the patient started on hemodialysis. Measure-
ments were done using ultrasound-indicated dilution techniques.
Baseline characteristics of the two study groups were similar, as were
graft blood flow rates at the time of baseline measurement. Of the grafts
placed, 94% were expanded polytetrafluoroethylene, and 5% were made
from some other synthetic materials. Twenty-nine percent of the grafts wereforearm grafts and 44% were in the upper arm, with 6% in the leg. The rate
of adherence to the study medication regimen was 83% in both groups.
At 1 year, primary unassisted patency was 23% (95% confidence interval
[CI], 18%-28%) in the placebo group and 28% (95% CI, 23%-35%) in the
dipyridamole-aspirin group. Adjusting for prespecified factors, the hazard
ratio (HR) for loss of primary unassisted graft patency in the dipyridamole
plus aspirin group compared with the placebo group was 0.82 (95% CI,
0.68-0.98; P .03). This provided a relative reduction in the rate of loss of
primary unassisted graft patency of 18%. The HR for loss of primary
unassisted graft patency in the dipyridamole-aspirin group compared with
the placebo group was 0.76 (95% CI, 0.60-0.96; P  .02) among patients
not receiving aspirin at baseline and 0.92 (95% CI, 0.68-1.24; P  .57)
among those receiving aspirin at baseline. There was an overall 28% reduc-
tion in rate of stenosis of 50% from treatment with dipyridamole plus
aspirin (HR, 0.72; 95% CI, 0.57-0.90; P .005). Mean duration of primary
patency was 5.8 months (95% CI, 4.3-7.1) in the extended-release dipyridamole-
aspirin group and 4.3 months (95% CI, 3.6-5.4) in the placebo group.
Comment: The data indicate that the combination of extended release
dipyridamole plus aspirin in patients who had not previously received aspirin
therapy had a statistically significant effect on extending primary patency of
hemodialysis access grafts. The effect was modest and not clinically impor-
tant. The aspirin and dipyridamole combination delayed by 6 weeks the
median time to loss of primary patency in patients with newly created
arteriovenous grafts. Put another way, the drug combination provides a
reduction in the number of patients with primary graft failure by one patient
for every 20 patients treated for 1 year. Because treatment with dipyridamole
plus aspirin can cost between $5000 and $2200 per year, it is unclear if this
therapy is cost-effective. The importance of this study is that it indicates that
pharmacologic therapy targeting intimal hyperplasia potentially can improve
the patency of dialysis access grafts. However, a better, more robust, effect
will be needed to change practice.
Increased Oxidant Activity Mediates Vascular Dysfunction in Vibra-
tion Injury
Hughes JM, Wirth O, Krajnak K, et al. J Pharmacol Exp Ther 2009;328:
223-30.
Conclusion:Vibration causes vascular dysfunction in digital arteries by
increasing levels of reactive oxygen species (ROS).
Summary: There are almost 1.5 million workers in the United States
exposed to hand-transmitted vibration. Extrapolated from epidemiologic stud-
ies, almost half of these workers will eventually present with somemanifestation
of hand-arm vibration syndrome (HAVS). Anatomically, the predominant
vascular disorder is increased constriction of digital arteries. HAVS can be
associatedwith smoothmuscle hypertrophy andmedial thickening, with overall
increases in wall-lumen ratios and a subsequent reduction in internal diameters
of the digital arteries. Little is known about the onset and progression of this
disease at the cellular and molecular level. The goal of the current study was to
examine the effects of vibration on functional responses of digital arteries and to
try and elicit the underlyingmechanisms of vibration injury. The authors used a
ratmodel of vibration injury and in preliminary work characterized the response
of the digital vessels in paws to vibration. They used control and vibrating paws
and then examined the digital arteries ex vivo to determine vascular responses
associated with acute vibration injury.
Rat paws were exposed to a vibrating platform (4 hours, 125 Hz,
constant acceleration of 49 m/s2). Digital artery function was assessed in
vitro with a myograph system. Experiments indicated that constriction to
phenylephrine or 5-hydroxytryptamine was reduced in digital arteries from
vibrated paws. After endothelium denudation, the agonist no longer im-
paired constriction in vibrated arteries. If -nitro-L-arginine methyl ester
(L-NAME) was used to inhibit nitric oxide synthase (NOS), there was
increased constriction in vibrated but not control arteries to phenylephrine
or 5-hydroxytryptamine. Nitric oxide activity was reduced in vibrated com-
pared with control arteries. There were increased endogenous levels of ROS
in vibrated compared with control arteries. Increased ROS levels were
abolished by L-NAME. Catalase, which degrades extracellular hydrogen
peroxide, increased constriction to phenylephrine or 5-hydroxytryptamine
in vibrated but not control arteries. It abolished vibration-induced depres-
sion and constrictor responses.
Comment: The study suggests that an uncoupling of endothelial NOS
in response to acute vibration increases ROS levels and subsequent vascular
dysfunction in vibrated digital arteries. The clinical implication is that
therapeutic strategies to augment nitric oxide activity or inhibit ROSmay be
beneficial in patients exposed to vibrating tools.
No-Show Rates in the Vascular Laboratory: Analysis and Possible
Solutions
Satiani B, Miller S, Patel D. J Vasc Interv Radiol 2009;20:87-91.
Conclusions: No-show rates for the vascular laboratory present a
significant opportunity for cost savings and improvement in efficiency.
No-show rates do not appear to be reduced by automated reminder systems.
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ing no-show rates in the clinical setting (J Am Board Fam Pract 2001;
14:193-6; JAMA 1992;267:1813-7). Telephone and mail reminders may
be useful for improving compliance with appointments in the physician’s
office. The effect of no-shows on the noninvasive vascular laboratory has
not been adequately studied. In addition, methods of improving no-
show rates have not been assessed for the vascular laboratory. In this
retrospective study, the authors thought to examine the financial and
scheduling effect of no-shows on the vascular laboratory. They also
reviewed methods to improve patient compliance as well as the literature
on “overbooking” to suggest techniques for reducing rates by extrapo-
lation from nonhealth care industries. They calculate the financial impact
of missed appointments by outpatients during a 9-month period. The
calculation was based on the weighted averaged reimbursement rates for
the technical component of a bilateral venous duplex examination. They
also studied the effect of an automated telephone reminder system on the
no-show rate during a subsequent 17-month period.
The overall no-show rate in the author’s vascular laboratory was 12%.
This was an average of 7.6 missed appointments per week in the outpatient
laboratory. Using the method of calculating financial effects noted above,
this translated into a gross revenue loss of approximately $89,000. There
were 8766 patients offered automated reminder calls, and 4648 (53%)
agreed to receive the call. However, the no-show rate was actually greater for
those patients who chose to receive automated reminder calls than those
who declined such a call (8.9% vs 5.9%, P  .0001).
Comment: Missed appointments are a ubiquitous problem and are
common to many industries other than health care. No-shows in the clinical
setting and in outpatient facilities represent lost revenue opportunities and
create inefficiencies from idle time and increased wait times for new appoint-
ments. This article confirms the adverse financial effect of no-shows on the
vascular laboratory’s bottom line. The discussion accompanying this article
is excellent and indicates particular strategies of overbookingmay be a partial
solution to the no-show problem in outpatient vascular laboratories but may
not be useful in laboratories that also serve a large inpatient population. The
primary limitation to this study is that it does not address the root causes of
patient no-shows. As the squeeze on health care dollars continues to tighten,
physicians will need to examine all aspects of their business and how to make
it more efficient.
Randomized Clinical Trial of Concomitant or Sequential Phlebectomy
After Endovenous Laser Therapy for Varicose Veins
Carradice D, Mekako AI, Hatfield J, et al. Brit J Surg 2009;96:369-75.Conclusions: Phlebectomy performed in conjunction with endovenous
laser therapy (EVLT) increases the length of the index procedure but reduces
the need for secondary procedures and improves quality of life and venous
symptoms.
Summary: It has been suggested that branch varicosities of the great
saphenous vein (GSV) can be left untreated at the time of GSV EVLT
because many patients after EVLT will not require or opt for subsequent
phlebectomy. Others advocate concomitant phlebectomy at the time of
EVLT, arguing that this reduces the need for secondary procedures. In this
study, the authors performed a randomized trial to evaluate and compare
ambulatory phlebectomy performed concomitantly with EVLT to the per-
formance of EVLT with late ambulatory phlebectomy as needed.
There were 50 patients with GSV distribution varicose veins ran-
domized to EVLT alone or EVLT with concomitant ambulatory phle-
bectomies (EVLTAP). Procedures were analyzed for procedure duration
and associated pain score. Requirements for secondary procedures and
quality of life after 3 months were analyzed. Quality of life was assessed
with Short Form 36 (SF-36) and EuroQol 5D scores and venous symp-
toms with the Venous Clinical Severity Score and the Aberdeen Varicose
Vein Questionnaire.
The EVLTAP procedures took longer but decreased the performance
of subsequent interventions. EVLTAP did not result in an increase in
immediate postprocedural pain or differences in SF-36 or EuroQol 5D
scores. The Venous Clinical Severity Score was lower at 3 months for
EVLTAP than EVLT alone (0 [range, 0-1] vs 2 [range, 0-2]; P  .001).
There were lower Aberdeen Varicose Vein Questionnaire scores at 6 weeks
(7.9 [range, 4.1-10.7] vs 13.5 [range, 10.9-18.1]; P  .001) in the
EVLTAP vs EVLT-only patients. Aberdeen Varicose Vein Questionnaire
scores were also lower at 3 months in the EVLTAP vs EVLT patients (2.0
[range, 0.4-7.7] vs 9.6 [range, 2.2-13.8]); P  .015). At 1-year after the
procedure, there were no differences in Venous Clinical Severity Scores or
Aberdeen Varicose VeinQuestionnaire scores in the EVLTAP vs EVLT-only
patients.
Comment: The article is severely limited by the small number of
patients in the study. There are too few patients to perform meaningful
analysis of clinically significant subgroups. A larger study stratifying patients
according to the size and number of their branch varicosities is needed.
Patients with only a few small branch varicosities are probably better off
without phlebectomy at the time of GSV ablation. However, patients with
larger branched varicosities or multiple branch varicosities may be best
treated with a concomitant procedure. Until trials with larger numbers are
available, physicians will still have to use individual judgment to determine
which patients with branch varicosities should be treated with selective late,
or routine concomitant, phlebectomy.
